⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5467583 | 0.67 | ADRA2A (0.30) | — | |
| SCHEMBL9774677 | 0.60 | — | — | |
| SCHEMBL64911 | 0.56 | — | — | |
| SCHEMBL5577058 | 0.49 | — | — | |
| SCHEMBL31299889 | 0.48 | — | — | |
| SCHEMBL2761125 | 0.48 | — | — | |
| SCHEMBL3937451 | 0.43 | — | — | |
| SCHEMBL3927193 | 0.41 | — | — | |
| SCHEMBL16460777 | 0.41 | — | — | |
| SCHEMBL10638296 | 0.36 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100266567-A1 | USE OF URATE OXIDASE FOR THE TREATMENT OR PROPHYLAXIS OF DISORDERS OR INDIRECT SEQUELAE OF THE HEART CAUSED BY ISCHEMIC OR REPERFUSION EVENTS | SANOFI-AVENTIS (FR) | 2010-10-21 | — | — | US | disclosed |
| EP-2197550-A1 | USE OF URATE OXIDASE FOR THE TREATMENT OR PROPHYLAXIS OF DISORDERS OR INDIRECT SEQUELAE OF THE HEART CAUSED BY ISCHEMIC OR REPERFUSION EVENTS | Sanofi-Aventis (FR) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009030373-A1 | USE OF URATE OXIDASE FOR THE TREATMENT OR PROPHYLAXIS OF DISORDERS OR INDIRECT SEQUELAE OF THE HEART CAUSED BY ISCHEMIC OR REPERFUSION EVENTS | SANOFI-AVENTIS (FR) | 2009-03-12 | — | — | WO | disclosed |
| EP-1420748-A4 | PEG-MODIFIED URICASE | PHOENIX PHARMACOLOGICS INC (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20050226859-A1 | Peg-Modified Uricase | PHOENIX PHARMACOLOGICS, INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-6913915-B2 | PEG-modified uricase | PHOENIX PHARMACOLOGICS, INC. (US) | 2005-07-05 | — | — | US | disclosed |
| EP-1420748-A2 | PEG-MODIFIED URICASE | Phoenix Pharmacologics, Inc. (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20030082786-A1 | Compound for use in the treatment of gout and tumors | SHENYANG SUNSHINE PHARMACEUTICAL COMPANY LIMITED (CN) | 2003-05-01 | — | — | US | disclosed |
| WO-2003011211-A2 | PEG-MODIFIED URICASE | PHOENIX PHARMACOLOGICS, INC. (US) | 2003-02-13 | — | — | WO | disclosed |